A randomized phase III trial of the Southern Italy Oncology Group (G.O.I.M.). of mitomycin C plus vindesine and cisplatin (MVP regimen) versus vinorelbine plus cisplatin (PV regimen) in stage III–IV non small cell lung cancer
Domenico Galetta(Istituto Tumori Bari), Giuseppe Colucci(Roche (Switzerland)), Vittorio Gebbia(Università degli Studi di Enna Kore), Ernesto Durini(Ito Hospital), Cesare Gridelli(Azienda Ospedaliera S.Giuseppe Moscati), Ferdinando Riccardi(Ospedale Antonio Cardarelli), Nicola Borsellino, A. C. Testa(Università Cattolica del Sacro Cuore)
Cited by 3
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Non-small-cell lung cancer
|Nature Reviews Disease Primers|2015|1.1k
Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial
|JNCI Journal of the National Cancer Institute|2003|795